title: Letter from the editor.
authors.affiliation: Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, Israel.
authors.forename: Ronald
authors.initials: R
authors.lastname: Ellis
authors.forename: Eva M
authors.initials: EM
authors.lastname: Riedmann
mesh_terms: D004769:Enterovirus Infections / Q000276:immunology / Q000517:prevention & control; D022362:Hepatitis A Vaccines / Q000276:immunology / Q000627:therapeutic use; D017325:Hepatitis B Vaccines / Q000276:immunology / Q000627:therapeutic use; D053061:Herpes Zoster Vaccine / Q000276:immunology / Q000627:therapeutic use; D006566:Herpesviridae Infections / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007252:Influenza Vaccines / Q000276:immunology; D053918:Papillomavirus Vaccines / Q000276:immunology / Q000627:therapeutic use; D011819:Rabies Vaccines / Q000276:immunology / Q000627:therapeutic use; D014765:Viral Vaccines / Q000276:immunology* / Q000627:therapeutic use*
chemical_list: D022362:Hepatitis A Vaccines; D017325:Hepatitis B Vaccines; D053061:Herpes Zoster Vaccine; D007252:Influenza Vaccines; D053918:Papillomavirus Vaccines; D011819:Rabies Vaccines; D014765:Viral Vaccines